Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Algernon Pharmaceuticals Inc (AGNPF)
Algernon Pharmaceuticals Inc (AGNPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AGNPF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0441 +29.48%
on 02/20/24
0.0735 -22.31%
on 02/01/24
-0.0010 (-1.72%)
since 01/22/24
3-Month
0.0441 +29.48%
on 02/20/24
0.0823 -30.62%
on 01/03/24
-0.0139 (-19.58%)
since 11/22/23
52-Week
0.0353 +61.76%
on 11/17/23
0.5420 -89.46%
on 03/08/23
-0.2984 (-83.94%)
since 02/23/23

Most Recent Stories

More News
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 0.0750 (-6.25%)
AGNPF : 0.0571 (-4.19%)
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 0.0750 (-6.25%)
AGNPF : 0.0571 (-4.19%)
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

VANCOUVER, British Columbia, July 07, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 0.0750 (-6.25%)
AGNPF : 0.0571 (-4.19%)
Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

VANCOUVER, British Columbia, July 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 0.0750 (-6.25%)
AGNPF : 0.0571 (-4.19%)
Algernon Pharmaceuticals Announces Closing of Public Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 04, 2022 (GLOBE NEWSWIRE) --...

AGN.CN : 0.0750 (-6.25%)
AGNPF : 0.0571 (-4.19%)
Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) --...

AGN.CN : 0.0750 (-6.25%)
AGNPF : 0.0571 (-4.19%)
Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) --...

AGN.CN : 0.0750 (-6.25%)
AGNPF : 0.0571 (-4.19%)
Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended

VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 0.0750 (-6.25%)
AGNPF : 0.0571 (-4.19%)
Algernon Pharmaceuticals Announces Public Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 15, 2022 (GLOBE NEWSWIRE) --...

AGN.CN : 0.0750 (-6.25%)
AGNPF : 0.0571 (-4.19%)
Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO)...

AGN.CN : 0.0750 (-6.25%)
AGNPF : 0.0571 (-4.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0571
2nd Resistance Point 0.0571
1st Resistance Point 0.0571
Last Price 0.0571
1st Support Level 0.0571
2nd Support Level 0.0571
3rd Support Level 0.0571

See More

52-Week High 0.5420
Fibonacci 61.8% 0.3484
Fibonacci 50% 0.2887
Fibonacci 38.2% 0.2289
Last Price 0.0571
52-Week Low 0.0353

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar